tetano
Editor, Senior Moderator
Antivir Ther. 2013 May 28. doi: 10.3851/IMP2629. [Epub ahead of print]
Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.
Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP.
Source
Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, USA.
Abstract
BACKGROUND:
Antivirals reduce influenza viral replication and illness measures particularly if initiated early within 48 hours of symptom onset. Whether experimental antivirals that reduce RSV load would also reduce disease is unknown. This study compares viral and disease dynamics in humans experimentally infected with influenza or RSV.
METHODS:
Clinical strains of RSV-A and influenza-A were inoculated intranasally into 20 and 17 healthy volunteers respectively on day 0. Symptom scores and nasal washes were performed twice daily, and daily mucus weights were collected. Viral loads in nasal washes were quantified by culture (plaque assay in HEp-2 cells for RSV and by endpoint dilution in MDCK cells for influenza).
RESULTS:
After influenza inoculation, influenza viral load and illness markers increased simultaneously until day 2. Within individual subjects, peak influenza load occurred 0.4 days (95% CI -0.4-1.3) before peak symptoms. Influenza viral load and disease declined thereafter. After RSV inoculation, a longer incubation period occurred prior to viral detection and symptom onset. RSV load and disease increased together until day 5. Within individual subjects, peak RSV loads occurred 0.2 days (95% CI -0.7-1.05) before peak symptoms, after which both illness measures and viral load declined together.
CONCLUSIONS:
Viral and disease dynamics in experimental human infections suggest that reducing RSV load, if timed similarly to clinically-effective influenza antivirals, might be expected to have a similar or greater window of opportunity for reducing clinical RSV disease.
PMID:
23714753
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23714753
Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.
Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP.
Source
Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, USA.
Abstract
BACKGROUND:
Antivirals reduce influenza viral replication and illness measures particularly if initiated early within 48 hours of symptom onset. Whether experimental antivirals that reduce RSV load would also reduce disease is unknown. This study compares viral and disease dynamics in humans experimentally infected with influenza or RSV.
METHODS:
Clinical strains of RSV-A and influenza-A were inoculated intranasally into 20 and 17 healthy volunteers respectively on day 0. Symptom scores and nasal washes were performed twice daily, and daily mucus weights were collected. Viral loads in nasal washes were quantified by culture (plaque assay in HEp-2 cells for RSV and by endpoint dilution in MDCK cells for influenza).
RESULTS:
After influenza inoculation, influenza viral load and illness markers increased simultaneously until day 2. Within individual subjects, peak influenza load occurred 0.4 days (95% CI -0.4-1.3) before peak symptoms. Influenza viral load and disease declined thereafter. After RSV inoculation, a longer incubation period occurred prior to viral detection and symptom onset. RSV load and disease increased together until day 5. Within individual subjects, peak RSV loads occurred 0.2 days (95% CI -0.7-1.05) before peak symptoms, after which both illness measures and viral load declined together.
CONCLUSIONS:
Viral and disease dynamics in experimental human infections suggest that reducing RSV load, if timed similarly to clinically-effective influenza antivirals, might be expected to have a similar or greater window of opportunity for reducing clinical RSV disease.
PMID:
23714753
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23714753